KR100236373B1 - Antioxidant food and antioxidant preparation - Google Patents
Antioxidant food and antioxidant preparation Download PDFInfo
- Publication number
- KR100236373B1 KR100236373B1 KR1019950700078A KR19950700078A KR100236373B1 KR 100236373 B1 KR100236373 B1 KR 100236373B1 KR 1019950700078 A KR1019950700078 A KR 1019950700078A KR 19950700078 A KR19950700078 A KR 19950700078A KR 100236373 B1 KR100236373 B1 KR 100236373B1
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- tea
- antioxidant
- lactobacillus plantarum
- sod
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 37
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract description 69
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 46
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 46
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 46
- 241000894006 Bacteria Species 0.000 claims abstract description 30
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 9
- 238000001727 in vivo Methods 0.000 claims abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 36
- 235000013618 yogurt Nutrition 0.000 claims description 20
- 235000014655 lactic acid Nutrition 0.000 claims description 18
- 239000004310 lactic acid Substances 0.000 claims description 18
- 235000013361 beverage Nutrition 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 108
- 239000011572 manganese Substances 0.000 abstract description 54
- 238000000855 fermentation Methods 0.000 abstract description 45
- 230000004151 fermentation Effects 0.000 abstract description 45
- 102000016938 Catalase Human genes 0.000 abstract description 41
- 108010053835 Catalase Proteins 0.000 abstract description 41
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract description 27
- 229910052748 manganese Inorganic materials 0.000 abstract description 27
- 239000005445 natural material Substances 0.000 abstract description 18
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 abstract description 4
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 62
- 235000013616 tea Nutrition 0.000 description 55
- 102000019197 Superoxide Dismutase Human genes 0.000 description 43
- 108010012715 Superoxide dismutase Proteins 0.000 description 43
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 27
- 235000006708 antioxidants Nutrition 0.000 description 22
- 241000186660 Lactobacillus Species 0.000 description 15
- 229940039696 lactobacillus Drugs 0.000 description 15
- 235000009569 green tea Nutrition 0.000 description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 9
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 201000005917 gastric ulcer Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 6
- 235000005487 catechin Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229950001002 cianidanol Drugs 0.000 description 5
- 235000015140 cultured milk Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019225 fermented tea Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- HAHASQAKYSVXBE-WAYWQWQTSA-N (z)-2,3-diethylbut-2-enedioic acid Chemical compound CC\C(C(O)=O)=C(/CC)C(O)=O HAHASQAKYSVXBE-WAYWQWQTSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241001609030 Brosme brosme Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940089151 indomethacin 20 mg Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000010447 natron Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B7/00—Preservation or chemical ripening of fruit or vegetables
- A23B7/10—Preserving with acids; Acid fermentation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/08—Oxidation; Fermentation
- A23F3/10—Fermentation with addition of microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dairy Products (AREA)
Abstract
본 발명의 항산화 식품은 차잎같은 망간 함유 천연물질을 가하고 락토바실로스 플란타룸같은 카탈라제 활성을 갖는 박테리아로 발효시켜 제조된 발효물이다 . 이는 수퍼옥사이드디스무타제-형 활성 및 카탈라제 활성을 모두 나타내며 소화관 내부를 포함하는 생체 내에서 항산화 활성을 나타낸다. 따라서, 활성 산소에 의한 질병의 예방에 효과적이다.The antioxidant food of the present invention is a fermentation product prepared by adding manganese-containing natural substances such as tea leaves and fermenting with bacteria having catalase activity such as lactobacillus plantarum. It exhibits both superoxide dismutase-type activity and catalase activity and exhibits antioxidant activity in vivo, including inside the digestive tract. Therefore, it is effective for the prevention of diseases caused by free radicals.
Description
[고안의 명칭][Designation name]
항산화 식품 및 항산화 제제Antioxidant Foods & Antioxidants
[도면의 간단한 설명][Brief Description of Drawings]
제1도는 MnCl2 첨가 또는 차 첨가에 따른 SOD형 활성 및 CAT 활성 변화를 도 시 한 그래프이다.1 is a graph showing changes in SOD type and CAT activity according to MnCl 2 addition or tea addition.
제2도는 유문-결찰된랫트에서락토바실루스플란타룸(Lactobacillusplantarum)으로 발효시켜 제조된 생성물 투여후 시간에 따른 SOD형 활성 변화를 도시한 그래프이다.FIG. 2 is a graph showing changes in SOD type activity over time after product administration prepared by fermentation with Lactobacillus plantarum in pyloric-ligation rats.
제3도는 유문-결찰된 랫트에서 락토바실루스 플란타룸으로 발효시켜 제조된생성물 투여후 시간에 따른 CAT 활성 변화를 도시한 그래프이다.FIG. 3 is a graph showing changes in CAT activity over time after product administration prepared by fermentation with Lactobacillus plantarum in pyloric-ligation rats.
제4도는 유문-결찰된 위장에서 생존가능한 세포수 변화를 도시한 그래프이다.4 is a graph depicting viable cell number changes in pyloric-ligated gastrointestinal tract.
제5도는 락토바실루스 플란타룸으로 발효시켜 제조된 차-첨가된 생성물의 발효 전후의 SOD형 활성을 도시한 그래프이다.5 is a graph depicting SOD type activity before and after fermentation of tea-added products prepared by fermentation with Lactobacillus plantarum.
제6도는 인도메타신으로 유발된 위궤양 모델에서 락토바실루스 플란타룸으 발효시켜 제조된 차-첨가된 생성물 투여후 효과를 도시한 그래프이다.FIG. 6 is a graph showing the effect after administration of a tea-added product prepared by fermenting Lactobacillus plantarum in a gastric ulcer model induced by indomethacin.
제7도는 락토바실루스 플란타룽으로 발효시켜 제조된 차-첨가된 생성물 투여 후 혈청에서의 SOD형 활성을 도시한 그래프이다.FIG. 7 is a graph depicting SOD type activity in serum after administration of tea-added product prepared by fermentation with Lactobacillus plantarung.
제8도는 과산화수소로 유발된 위점막 병변에 대한 락토바실루스 플란타룸으로 발효시켜 제조된 차-첨가된 생성물 투여후 효과를 도시한 그래프이다.FIG. 8 is a graph showing the effect after administration of a tea-added product prepared by fermentation with Lactobacillus plantarum on hydrogen peroxide induced gastric mucosal lesions.
제9도는 차 추출액 및 MnCl2의 MPO 활성 억제 효과를 도시한 그래프이다.9 is a graph showing the effect of inhibiting MPO activity of tea extract and MnCl 2.
제10도는 카테친의 MPO 활성 억제 효과를 도시한 그래프이다.10 is a graph showing the effect of catechins inhibiting MPO activity.
[기술 분야][Technical Field]
본 발명은 수퍼옥사이드(O2-) 및 과산화수소(H2O2)를 제거함으로써, 활성 산소에 의해 야기되는 질병을 예방하거나 호전시키기 위한 항산화 식품, 항산화 제제 및 항산화 방법에 관한 것이다.The present invention relates to antioxidant foods, antioxidant preparations and antioxidant methods for preventing or ameliorating diseases caused by free radicals by removing superoxides (O2-) and hydrogen peroxide (H2O2).
[배경 기술]Background Technology
메치니코프의 장수이론 이후로 유산균 또는 유산균을 사용한 식품의 생리학적 효과에 대해 다양하게 연구되어 왔다.Since Mechinnikov's theory of longevity, various studies have been conducted on the physiological effects of lactic acid bacteria or foods using lactic acid bacteria.
요거트와 같은 발효유에 함유된 유산균의 작용으로서 장내 미생물총 개량 효과 및 정장 작용 등이 익히 공지되어 있다. 최근에, 유산균이 다양한 기능, 예를들어 면역 활성 작용, 항군 작용 및 항종양 작용 등을 갖는다고 보고되었다. 상술한 바와 같이, 유산균의 다양한 건강 효과가 기대되기 때문에 , 또한 사람의 장에서 검출되는 락토바실루스 아시도필루스(Lactobacillus acidophilus), 락토바실루스 카제미(Lactobacillus casei) 및 비피도박테리움(Bifidobsvyrtium) 속 같은 균주를 사용하는 발효유 및 유산균 음료가 시판되고 있다.As the action of lactic acid bacteria contained in fermented milk, such as yoghurt, the intestinal microflora improvement effect and intestinal action are well known. Recently, it has been reported that lactic acid bacteria have various functions, such as immune activity, anti-group action and anti-tumor action. As described above, since various health effects of lactic acid bacteria are expected, Lactobacillus acidophilus, Lactobacillus casei and Bifidobsvyrtium genus, which are also detected in the human intestine Fermented milk and lactic acid bacteria beverages using the same strain are commercially available.
한편, 활성 산소는 백혈구의 살균 작용과 같은 생물학적 보호 인자로서 중요하나, 생체내의 활성 산소의 과도한 생성은 다양한 조직 질병을 일으킨다는 것은 명백하다.On the other hand, free radicals are important as biological protective factors such as the bactericidal action of leukocytes, but it is clear that excessive production of free radicals in vivo causes various tissue diseases.
활성 산소를 발생시키는 통상의 인자로서, 스트레스, 알콜, 과산화물, 약물 및 운동 등이 공지되어 있다. 이러한 인자에 의해 발생되는 활성 산소 및 리포퍼 옥사이드는 뇌신경 질환, 순환기 질환, 암, 소화관 질환, 간 질환, 동맥경화, 신장 질환, 당뇨병 및 노화 등과 밀접하게 관련됨이 지적된다.As common factors for generating free radicals, stress, alcohols, peroxides, drugs, exercise and the like are known. It is pointed out that the active oxygen and the reporter oxide caused by these factors are closely related to cranial nerve disease, circulatory disease, cancer, digestive tract disease, liver disease, arteriosclerosis, kidney disease, diabetes and aging.
생체는 산소 독성으로부터 스스로를 보호하기 위해 일련의 산화 보호 시스템을 갖는다. 한편, 이러한 시스템을 정상적으로 작용시키기 위해 산화 영양 성분을 충분히 섭취하는 것이 중요하다. 천연 산화 영양 성분으로서, 비타민 E, 비타민 C, β-카로텐, 폴리페놀 및 미량원소(예: 셀레늄, 구리 , 아연 등)가 공지되어 있다. 항산화 작용을 제공하기 위해, 이러한 영양 성분을 함유하는 식품이 개발되었다.The living body has a series of oxidation protection systems to protect itself from oxygen toxicity. On the other hand, it is important to consume enough oxidized nutrients in order to function normally. As natural oxidizing nutrients, vitamin E, vitamin C, β-carotene, polyphenols and trace elements such as selenium, copper, zinc and the like are known. To provide antioxidant activity, foods containing these nutrients have been developed.
생체내의 항산화 메카니즘은 이의 작용에 따라 예방적 항산화 작용(라디칼 생성 조절) 및 연쇄적 절단형 항산화 작용(이미 생성된 라디칼의 소거 및 제거)으로 개략적으로 분류된다. 예방적 항산화 작용을 갖는 것의 예로는 수퍼옥사이드 디스뮤타제(SOD), 카탈라제(CAT) 및 글루타티온 퍼옥시다제(GSH-Px) 등과 같은 효소가 포함된다. 연쇄적 절단형 항산화 작용을 갖는 것의 예로는 상술한 항산화 영양 성분이 포함된다.Antioxidant mechanisms in vivo are roughly classified according to their action into prophylactic antioxidant action (regulating radical production) and chain cleavage antioxidant action (scavenging and elimination of already generated radicals). Examples of prophylactic antioxidant actions include enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) and the like. Examples of those having a chain cleaved antioxidant action include the antioxidant nutritional components described above.
그러나, 통상적인 식품에서, 지질 과산화와 관련된 수퍼옥사이드(O2-) 및 과산화수소(H2O2)의 연쇄적 제거를 수행하는 제품은 전혀 공지되어 있지 않다.In conventional foods, however, no products are known which perform the serial removal of superoxides (O2-) and hydrogen peroxide (H2O2) associated with lipid peroxidation.
본 발명의 목적은 수퍼옥사이드 디스뮤타제(이후엔 "SOD"로 언급)-형 활성 및 카탈라제(이후엔 "CAT"로 언급) 활성을 동시에 발현하는, 예방적 항산화 작용에서 특히 우수한, 항산화 식품, 항산화 제제 및 항산화 방법을 제공하는 것이다.An object of the present invention is an antioxidant food, antioxidant preparation, which is particularly good in prophylactic antioxidant action, which simultaneously expresses superoxide dismutase (hereinafter referred to as "SOD")-type activity and catalase (hereinafter referred to as "CAT") activity. And an antioxidant method.
[발명의 개시][Initiation of invention]
본 발명의 항산화 식품은 망간-함유 천연 물질을 첨가하고 CAT 활성을 갖는 박테리아로 발효시켜 제조된 발효 제품을 포함하는, 소화관의 내부를 포함하는 생체에서 항산화 작용을 갖는다.Antioxidant foods of the present invention have antioxidant activity in vivo including the interior of the digestive tract, including fermentation products prepared by adding manganese-containing natural substances and fermenting with bacteria having CAT activity.
즉, 본 발명자들은 다양한 유산균 중에서 특정 박테리아는 망간이 존재하지 않는 환경에서는 CAT 활성을 나타내지 않으나, 증식 환경에 망간이 존재하는 경우 세포내로 망간을 혼입하여 Mn-CAT 활성 및 SOD형 활성을 동시에 발현한 다는 사실을 인지하여 본 발명을 완성하였다. 본 발명의 항산화 식품은 예방적 항산화 식품으로서 특히 적합하다.In other words, the present inventors do not exhibit CAT activity in a variety of lactic acid bacteria in an environment where manganese does not exist, but when manganese is present in a proliferative environment, Mn-CAT activity and SOD type activity are simultaneously expressed by incorporating manganese into cells. Recognized that the present invention was completed. The antioxidant food of the present invention is particularly suitable as a prophylactic antioxidant food.
Mn-CAT는 철을 함유하는 heme-CAT와 비교하여 다양한 억제제, 개질제, 킬레이트제 등에 의해 영향받지 않으며 광범위한 pH 및 온도내에서 안정성을 나타낸다.Mn-CAT is unaffected by various inhibitors, modifiers, chelating agents and the like compared to heme-CAT containing iron and exhibits stability over a wide range of pH and temperatures.
또한, 본 발명의 항산화 식품은 상술한 바와 같은 발효 제품 이외에 건조 제품, 바람직하게는 CAT 활성을 갖는 박테리아 및 망간-함유 천연 물질을 함유하는 동결 건조 제품일 수 있다.In addition, the antioxidant food of the present invention may be a freeze-dried product containing a dry product, preferably bacteria and manganese-containing natural substances having CAT activity, in addition to the fermentation product as described above.
또한, 본 발명은 CAT 활성을 갖는 박테리아 및 망간-함유 천연 물질을 포함하는 항산촤 제제를 제공한다. 이러한 항산화 제제는 건조 제품(정제, 산제, 입제, 캡슬제 등의 형태) 또는 액체 형태일 수 있다.The present invention also provides an anti-acid preparation comprising bacteria and manganese-containing natural substances having CAT activity. Such antioxidant preparations may be in dry form (in the form of tablets, powders, granules, capsules, etc.) or in liquid form.
더우기, 본 발명에 따라서, 망간 함유 천연 물질을 가하고, CAT 활성을 갖는 박테리아로 발효시켜 제조된, SOD형 활성 및 CAT 활성을 동시에 나타내는 발효 제품을 섭취함을 포함하는, 소화관 내부를 포함하는 생체내에서 의 항산화 방법을 제공한다.Furthermore, according to the present invention, in vivo, including the digestive tract, incorporating a manganese-containing natural substance and ingesting a fermentation product simultaneously exhibiting SOD type and CAT activity, prepared by fermentation with bacteria having CAT activity. Provides antioxidant methods for
[발명의 실시를 위한 최선의 형태]Best Mode for Implementation of the Invention
본 발명에서 Mn-CAT 활성을 갖는 박테리아의 예는 락토바실루스로서 락토바 실루스 플란타룸[ATCC14431 균주]을 포함한다.Examples of bacteria having Mn-CAT activity in the present invention include Lactobacillus plantarum [strain ATCC14431] as Lactobacillus.
박테리아의 분류학에서, 유산균은 CAT 활성을 전혀 가지지 않는 것으로 알려져 있다. 그러나, 증식 환경중에 망간이 존재하는 경우, 상술한 락토바실루스 플란타룸은 망간을 이의 세포내로 혼입시켜 Mn-CAT 활성을 발현시킨다. 한편, Mn은 SOD의 중심 금속으로서 작용하며 Mn 자체는 SOD형 활성을 갖는 것으로 공지되어 있다. 따라서, 망간-함유 천연 물질 존재하에 락토바실루;스 플란타룸으로 발효시킴으로써 SOD형 활성과 CAT 활성을 동시에 갖는 발효 제품을 제조하는 것이 가능해졌다.In bacterial taxonomy, lactic acid bacteria are known to have no CAT activity. However, when manganese is present in the proliferative environment, the above-described Lactobacillus plantarum expresses Mn-CAT activity by incorporating manganese into its cells. On the other hand, Mn acts as the central metal of SOD and Mn itself is known to have SOD type activity. Thus, by fermentation with lactobacillus; plantarum in the presence of manganese-containing natural materials, it has become possible to produce fermentation products having both SOD type activity and CAT activity.
최근에, 류마티즘, 심장허혈 등에 대한 SOD의 임상적 사용이 진행되었다.Recently, clinical use of SOD for rheumatism, cardiac ischemia and the like has advanced.
그러나, SOD만을 사용하는 경우 과산화수소의 국소량이 증가하며 최대의 라디칼 반응성을 갖는 하이드록시 라디칼( . OH)이 형성된다는 심각한 문제점이 있다. 따라서, SOD를 사용하는 경우 CAT 및 GSH-Px를 배합하여 사용함으로써 O2- 및 과산화수소를 제거하는 것이 중요하다. 따라서, 상기와 같은 이유에 따라서, Mn을 락토바실 루스 플란타룸에 가함으로써 수득한 SOD형 및 CfT 사이의 커플링 작용이 매우 중요 한 것으로 간주된다.However, when only SOD is used, there is a serious problem that a local amount of hydrogen peroxide is increased and hydroxy radical (.OH) having maximum radical reactivity is formed. Therefore, when using SOD, it is important to remove O2- and hydrogen peroxide by combining CAT and GSH-Px. Therefore, for the same reason as above, the coupling action between SOD type and CfT obtained by adding Mn to Lactobacillus loose plantarum is considered to be very important.
또한. 맏간 자체가 SOD가 생성되지 않는 겪무에도 SOD형 활성을 갖기 때문에락토바실루스 플란타룸 이외에 CAT 활성을 갖는 박테리아를 사용함으로써 락토바실 루스 플란타룽과 류일한 효과를 수득찰 수 있는 것으로 간주된다. 락토바실루스 플란타룸 끼치에 Mn-CAT 활성을 갖는 박테리아의 예는 페디오코쿠스 펜토사세우스 (Pediococcus pentosaceus), 페디오코쿠스 아시딜락티시(P. acidilactici) 및 테르 몰레필룸 알붐(Thermolephilum album) 등을 포함한다.Also. It is considered that the same effect as Lactobacillus plantarung can be obtained by using bacteria having CAT activity in addition to Lactobacillus plantarum because the elder itself has SOD-type activity even in the absence of SOD production. Examples of bacteria having Mn-CAT activity in Lactobacillus plantarum tusks are Pediococcus pentosaceus, Pediococcus asidilacti and Termolephilum alboom. And the like.
또한, 본 발명의 항산화 식품 또는 항산차 제제는 상술한 발효 제품 이외에 건조 제품, 바람직하게는 CAT 활성을 갖는 박테리아 및 망간-함유 천면 물질을 포함하는 돈결 건조 게품일 수 있다. 건조 제품은 산제, 씹제 및 정제 등의 모든 형태일 수 있다. 건조 제품은 그대로 섭취하거나 건조 제품을 시판되는 우유에 가하고 혼합물을 발효시켜 요거트를 재조한 후 섭취할 수 있다. 또한 건조 제품 이외에 냉류 제품 형태일 수 있다.In addition, the antioxidant food or antioxidant tea preparation of the present invention may be a dried product containing a dry product, preferably a bacterium having CAT activity and a manganese-containing cotton material, in addition to the above-mentioned fermentation product. Dry products can be in all forms such as powders, chew and tablets. The dried product may be taken as is or after the dry product is added to commercially available milk and the mixture is fermented to produce the yoghurt. It may also be in the form of a cold product in addition to the dry product.
본 발명에서 망간-함유 천연 물질은 박테리아 세포에 망간을 공급하는데 사용된다. 땅간 자체는 식푼 정가제고서 허용피지 않기 때문에 무기 화합물로서 망간을 가하는 것은 불가능하며, 따라서 천연 물질을 사용한다. 대량의 망간을 함유하는 천연 물질의 예는 차, 채소(예 : 양배추, 시금치 등) 및 풀잎 등과 같은 식물을 포함한다. 따라서, 이러한 식물을, CAT 활성을갖는 박테리아에 CAT 활성 및 SOD형 활성을 발현하는데 필요한 망간을 공급할 정도로 가하는 것이 중요하다 특히, 차는 카테친, 비타민 C 및 다양한 미량원소 등과 같은 항산화 성분을 다수 함유하기 때문에 높은 첨가 효과를 수득할 수 있다.In the present invention, manganese-containing natural materials are used to supply manganese to bacterial cells. Since the ground itself is not allowed to be charged, it is impossible to add manganese as an inorganic compound, and thus use natural materials. Examples of natural substances containing large amounts of manganese include plants such as tea, vegetables (eg cabbage, spinach, etc.) and blades of grass. Therefore, it is important to add such plants to the bacteria having CAT activity to supply manganese necessary for expressing CAT activity and SOD type activity. In particular, since tea contains many antioxidants such as catechin, vitamin C and various trace elements, A high addition effect can be obtained.
특히 락토바실루스 플란타룸에 차를 가하면 SOD형 활성 및 CAT 활성이 발현 될 뿐만 아니라 무기 Mn 화합물(예: 염화망간 MrC12 등)을 사용하는 경우와 비교하여 SOD형 활성이 극히 높으며 또한 위액에 노출되는 경우 SOD형 활성 및 CAT 활성이 장기간 유지될 수 있다.In particular, the addition of tea to Lactobacillus plantarum not only expresses SOD activity and CAT activity, but also results in extremely high SOD activity and exposure to gastric juice compared to the case of using inorganic Mn compounds (e.g., manganese chloride MrC12). SOD activity and CAT activity can be maintained for a long time.
박테리아로 인해 망간의 혼입이 용이해지기 때문때 차나 다른 천연 물질을 분말 형태로 가하는 것이 바람직하다. 천연 물질을 물 및/또는 수혼화성 유기용매 (예: 에틸 알콜과 같은 알콜 등)로 추출한 후, 물과 불혼화성인 유기용매(예: 클로로포름, 에틸 아세테이트, 부탄을 등)로 추출하여 유기상과 수성상을 분리하고, 수성상으로부터 용해된 고체 성분을 회수한 후 건조시킴으로써 분쇄시킨다. 또한, 고체 성분을 물 및/또는 수혼화성 유기용매로 추출한 용액으로부터 회수한 후 분쇄할 수 있다. 또한, 물로 천연 물질을 추출함으로써 제조된 수용액을 분쇄하지 않고 그 상태로 가하거나, 천연 물질을 미세하게 분쇄하여 수득한 것을 그 상태로가할 수 있다.Since bacteria facilitate the incorporation of manganese, it is desirable to add tea or other natural substances in powder form. The natural material is extracted with water and / or water miscible organic solvents (e.g. alcohols such as ethyl alcohol) and then extracted with an organic solvent that is immiscible with water (e.g. chloroform, ethyl acetate, butane, etc.) The phases are separated and the solid component dissolved from the aqueous phase is recovered and then ground by drying. The solid component can also be recovered from the solution extracted with water and / or water miscible organic solvent and then ground. In addition, the aqueous solution prepared by extracting the natural substance with water can be added in its state without being pulverized, or what has been obtained by finely pulverizing the natural substance can be added in that state.
차의 예로는 녹차(비발효 차), 예를 들어, 정제녹차, 분말차, 중간등급의 녹차, 미처리자, 분제차. 배종차, 구운차 등; 발효차, 예를 들어 흑차 등; 반-발효차, 예를 들어 오곤차, 파오총차(자스민차) 등이 포함된다.Examples of tea include green tea (non-fermented tea), for example, refined green tea, powdered tea, medium grade green tea, untreated, powdered tea. Seeded tea, roasted tea and the like; Fermented teas such as black tea and the like; Semi-fermented teas such as ogon tea, pao tea (jasmine tea) and the like.
발효 제품의 경우, 망간-함유-천연 물질의 양(망간의 양)은 제품 lKg당 바람직하게는 약 4 내지 20mg, 더욱 바람직하게는 약 4 내지 8mg이다. 박테리아 세포, 망간-함유 천연 물질 및 부형제를 주로 포함하는 건조 제품의 경우, 망간-함유 천연 물질의 방(망간의 양)은 제품 10g당 바람직하게는 약 4 내지 20mg, 더욱 바람직하게는 약 4 내지 8mg이다.For fermented products, the amount of manganese-containing-natural substance (amount of manganese) is preferably about 4-20 mg, more preferably about 4-8 mg per lKg product. For dry products comprising mainly bacterial cells, manganese-containing natural substances and excipients, the room of manganese-containing natural substance (amount of manganese) is preferably about 4 to 20 mg, more preferably about 4 to 10 g per product. 8 mg.
본 발명의 항산화 삭품 영태의 대표적인 예는 상술한 바와 같이 발효 제품 및 (동결)건조 제품을 포함한다.Representative examples of the antioxidative processed products of the present invention include fermented products and (frozen) dried products as described above.
본 발명의 발효 제품쓴 발효유, 예를 들어 요거트 및 유산균 음료를 포함한다. 발효유는 예정량의 망간-함유 천연 물질을 우유 또는 탈지유 1 ℓ에 가하고, CAT 활성을 갖는 유산균으로 접종시켜 35 내지 37℃에서 약 12 내지 72시간 동안 발효시켜 수득할 수 있다. 유산균 출발물의 양과 가해질 망간-함유 천연 물질의 양, 발효 시간 등을 조절함으로써 고형 요거트(정치 요거트). (반고형)요거트 (교반 요거트) 및 끽상 요거트(음료형 요거트)를 제코할 수 있다. 또한. 감미제(예:글루로즈, 수르로편. 통), 과윳(체: 포도. 사과, 도렌지. 레몬 등), 무기질 공급원으로서 무기 전해질(체: 염화나트륨. 염화칼륨. 염화마그네슘. 염화칼숨 등), 비타민, 향료 등을 발효유에 적당히 가할 수 있다.Fermented products of the present invention include bitter fermented milk, such as yoghurt and lactic acid bacteria beverages. Fermented milk can be obtained by adding a predetermined amount of manganese-containing natural substance to 1 L of milk or skim milk, inoculating with lactic acid bacteria having CAT activity and fermenting at 35 to 37 ° C. for about 12 to 72 hours. Solid yoghurt (political yoghurt) by controlling the amount of lactobacillus starting material, the amount of manganese-containing natural substance to be added, fermentation time and the like. You can offer (semi-solid) yogurts (stirred yogurts) and squeezed yogurts (drink-type yogurts). Also. Sweeteners (e.g., glurose, surlophine, kegs), fruit juice (sieve: grapes, apples, donge, lemon, etc.), mineral electrolytes (sieve: sodium chloride, potassium chloride, magnesium chloride, calcium chloride, etc.), vitamins as mineral sources , Fragrances, etc. may be appropriately added to the fermented milk.
또한, 유산균 음료는 탈지유 및 당(예: 글루코즈, 수크로즈 등)의 혼합 용액에 예정량의 망간-함유 천연 물질을 가하고 혼합 용액을 CAT 활성을 갖는 유산균으로 접종시켜 35 내지 37℃에서 약 12 내지 72시간 동안 발효시켜 수득할 수 있다. 요거트(예: 액상, 쥬스형 등)를 희석액(예: 물, 과일쥬스 등)에 대한 탈지유의 비율에 따라 제조할 수 있다. 발효될 기본 재료로서, 탈지유 이외에 유청, 저지방 우유 등이 사용될 수 있다. 희석액의 예는 물 이외에 과육, 락토커피 등이 있다.In addition, the lactic acid bacteria beverage is inoculated with a predetermined amount of manganese-containing natural substance to a mixed solution of skim milk and sugar (e.g., glucose, sucrose, etc.), and the mixed solution is inoculated with lactic acid bacteria having CAT activity at about 12 to 72 ° C. Can be obtained by fermentation for a time. Yoghurts (eg liquids, juices, etc.) may be prepared according to the ratio of skim milk to diluents (eg water, fruit juices, etc.). As the base material to be fermented, whey, low fat milk and the like can be used in addition to skim milk. Examples of diluents include pulp, lacto coffee, etc. in addition to water.
본 발명의 건조 제품은 약 5 ×108 내지 5 ×1010개의 박테리아 세포를 망간-함유 천연물질 2 내지 4g과 혼합하고, 혼합물에 부형제를 가한 후 건조시켜 수득한다. 부형제의 예는 락토즈, 글루코즈, 수크로즈 및 올리고사카라이드 등이 포함된다.The dried product of the present invention is obtained by mixing about 5 x 108 to 5 x 1010 bacterial cells with 2 to 4 g of manganese-containing natural material, adding an excipient to the mixture and then drying. Examples of excipients include lactose, glucose, sucrose, oligosaccharides, and the like.
본 발명의 건조 제품은 그 상태로 섭취되거나, 건조 제품을 우유에 가하고 혼합물을 12 내지 24시간 동안 실온에서 발효시켜 가정에서 요거트를 제조한 후 섭취할 수 있다.The dry product of the present invention can be taken as it is, or after the dry product is added to milk and the mixture is fermented at room temperature for 12 to 24 hours to make yoghurt at home.
[산업상 이용가능성][Industry availability]
상술한 바와 같이, 본 발명의 항산화 식품 및 항산화 제제는 SOD 활성 및 CAT 활성을 동시에 발현시킬 수 있으며 수퍼옥사이드 및 과산화물을 제거할 수 있다. 따라서 . 이들은 활성 산소에 의해 야기되는 질병 예방에 효과적이다.As described above, the antioxidant foods and antioxidant agents of the present invention can express SOD activity and CAT activity simultaneously and can remove superoxides and peroxides. therefore . They are effective in preventing diseases caused by free radicals.
[실시예]EXAMPLE
시험 실시예 1Test Example 1
(락토바실루스 플란파룸으로 발효시켜 제조한 차-첨가된 생성물의 시험관내 SOD형 활성 및 CAT 활성)(In Vitro SOD and CAT Activity of Tea-Added Products Prepared by Fermentation with Lactobacillus Planparum)
APT 배양액(DIFCO Ltd.에서 시판되는 "박토 트립톤" ; 이스트 추출물: 글루코즈; 나트론 시트레이트: 명화나트륨; 인산수소이칼륨; 황산마그네슘 및 탄산나트륨을 한유)중에서 락토바실루스 플란타룸을 배양(발효)하는 경우, MnCl2 또는 차(분말 녹차)를 배지에 가하여 Mn 농도가 각각 12μM. 50μM. 100μM 및 200μM이 되게 하고 박테리아 세포의 SOD형 활성 및 CATT 활성 및 MnC12 또는 차를 함유하는 완전 배지의 SOD형 활성 및 CAT활성을 박테리아 분열이 최대가 되는 지점에서 16시간 동안 배양만 후에 조사한다.Cultivation (fermentation) of Lactobacillus plantarum in APT cultures ("Bottom tryptone" sold by DIFCO Ltd .; yeast extract: glucose; natron citrate: sodium pyrophosphate; dipotassium hydrogen phosphate; magnesium sulfate and sodium carbonate) MnCl 2 or tea (powder green tea) was added to the medium, and the Mn concentration was 12 µM, respectively. 50 μM. 100 μM and 200 μM and the SOD type activity and CATT activity of bacterial cells and SOD type activity and CAT activity of complete medium containing MnC12 or tea are investigated only after incubation for 16 hours at the point of maximum bacterial division.
SOD형 활성은 NBT 환원법으로, CAT 활성은 과산화수소 감소 속도로 측정하며 결과는 제1노에 도시되어 있다.SOD type activity is measured by NBT reduction method, CAT activity is measured by the rate of hydrogen peroxide reduction and the results are shown in the first furnace.
제1도로부터 알 수 있는 바와 같이 SOD형 활성은 두 경우(MnC12/차 첨가 경 우)에서 가해진 Mn의 양과 비례하여 증가하나, 차 첨가의 경우 SOD 활성의 절대값 은 보다 크다(Mn 200μM이 가해지는 경우 약 35배).As can be seen from Figure 1, SOD activity increases in proportion to the amount of Mn added in both cases (MnC12 / tea addition), but the absolute value of SOD activity is higher for tea addition (Mn 200 μM added About 35 times if you lose).
CAT 활성은 Mn이 가해지지 않을 경우의 검출 한계보다 낮다. 한편, Mn 12.5μM 이상을 첨가함으로써 두 경우(MnCl2/차의 첨가 경우) 에서 APT 배지의 약1800U/200m1의 활성이 발현된다.CAT activity is lower than the detection limit when no Mn is applied. On the other hand, by adding at least 12.5 μM of Mn, the activity of about 1800 U / 200 ml of APT medium is expressed in both cases (in case of addition of MnCl 2 / tea).
한편, SOD 및 CAT의 작용은 O2- 및 H2O2의 제거이다. 그러나, SOD 및 CAT는 효소이며 따라서 SOD 및 CAT는 경구로 섭취하는 경우에도 활성이 약화되며 전혀 효과가 없다고 한다. 그러나, SOD 활성 및 CAT 활성은 락토바실루스 플란타룸으로 발효시켜 생성된 Mn-첨가된 생성물의 경우 박테리아 세포내에 보유되기 때문에, 이러한 활성은 박테리아가 사멸될 때까지는 보유된다고 예상된다. 또한, 상술한 바와 같이, Mn 자체 및 차에서의 성분은 SOD형 활성을가지나 효소는 아니기 때문에, 쉽게 활성이 저하되지 않는 것으로 간주된다.On the other hand, the action of SOD and CAT is the removal of O2- and H2O2. However, SOD and CAT are enzymes, so SOD and CAT are weakened and ineffective even when taken orally. However, since SOD activity and CAT activity are retained in bacterial cells for Mn-added products produced by fermentation with Lactobacillus plantarum, this activity is expected to be retained until the bacteria are killed. In addition, as described above, the components in Mn itself and in the car have SOD-type activity but are not enzymes, so it is considered that activity is not easily reduced.
상기 사실을 입증하기 위해, 락토바실루스 플란타룸으로 발효시켜 제조된 차-첨가된 생성물을 유문-결찰된 랫트에 강제로 경구투여하고, 투여 후 SDD형 활성 및 CAT 활성의 시간에 따른 변화를 하기 시험 실시 예에서 조사한다.To demonstrate this fact, tea-added products prepared by fermentation with Lactobacillus plantarum are forced orally administered to pyloric-ligation rats, and the time-dependent changes in SDD type activity and CAT activity following administration Investigate in the test examples.
시험 실시예 2Test Example 2
( 유문- 결찰된 랫트의 위장에서 락토바실루스 플란타룸으로 발효시켜 제조된 생성물의 SOD형 활성 및 CAT 활성 보유)(Retains SOD type and CAT activity of products prepared by fermentation with Lactobacillus plantarum in the gastrointestinal tract of pyloric-ligated rats)
SD 숫컷 랫트(중량: 250g)의 유문을 결찰시킨 직후, 락토바실루스 플란타룸으로 발효시켜 제조한 생성물 5ml를 경구 프로브를 사용하여 투여하고 위장의 내용물을 시간에 따라 회수하여 SOD형 활성 및 CAT 활성 변화를 조사한다. 결과는 제2도 및 제3도에 도시되어 있다. 또한, 시험 생성물은 APT 배양액에 50μM의 농도(Mn의 농도)로 MnC12 또는 차(분말 녹차)를 가하여 수득하며, 락토바실루스 플란타룸으로 접종시켜 16시간 동안 발효시킨다.Immediately after ligation of the pylorus of SD male rats (weight: 250 g), 5 ml of the product prepared by fermentation with Lactobacillus plantarum was administered using an oral probe, and the contents of the stomach were recovered over time to obtain SOD type and CAT activity. Investigate the change. The results are shown in FIGS. 2 and 3. In addition, the test product is obtained by adding MnC12 or tea (powdered green tea) to the APT culture at a concentration of 50 μM (concentration of Mn), and inoculated with Lactobacillus plantarum and fermented for 16 hours.
제2도로부터 알 수 있는 바와 같이, MnC12 첨가의 경우,SOD형 활성은 30분 동안 초기값의 약 35%로 감소하며 60분이 경과될 때까지 제거된다. 반대로, 차의 첨가의 경우, 높은 활성이 3시간이 경과할 때까지 보유된다.As can be seen from FIG. 2, for MnC12 addition, SOD activity decreases to about 35% of initial value for 30 minutes and is removed until 60 minutes have elapsed. In contrast, for the addition of tea, high activity is retained until 3 hours have elapsed.
제3도에서 알 수 있는 바와 같이 MnC12 첨가의 경우, SOD형 활성과 유사하게CAT 활성은 30분 동안 초기값의 약 80%로 감소한다. 한편, 차를 첨가한 그룹의 경우 CAT 활성은 초기값의 약 20% 정도 증가하며 60분 동안 초기값과 동일한 활성이 발현된다. 또한, 3시간 후에도 약간(약 15%)의 활성이 유지된다.As can be seen in FIG. 3, for MnC12 addition, similar to SOD type activity, CAT activity decreases to about 80% of initial value over 30 minutes. On the other hand, in the tea-added group, CAT activity is increased by about 20% of the initial value and the same activity as the initial value is expressed for 60 minutes. In addition, some activity (about 15%) is maintained after 3 hours.
제4도에서 알 수 있는 바와 같이, 경구투여 후, MnC12 첨가의 경우 생존가능한 세포수는 60분 동안 초기값의 약 1/1000로 감소한다. 3시간 후, 박테리아 세포는 검출되지 않는다. 한편 차플 첨가한 그룹의 겸뚜. 투여 전 생존가능한 세포수가 60분까지 보유된다. 3시간 후, 박테리아 세포는 검출되지 않는다. 제4도에서 "ND"는 생존가능한 세포수가 검출한계(104)보다 낮음을 의미한다.As can be seen in FIG. 4, after oral administration, viable cell numbers for MnC12 addition decrease to about 1/1000 of the initial value for 60 minutes. After 3 hours, bacterial cells are not detected. Meanwhile, the group of chaff added. Viable cell numbers are retained up to 60 minutes prior to administration. After 3 hours, bacterial cells are not detected. “ND” in FIG. 4 means that the viable cell number is lower than the detection limit 104.
상술한 바와같이, 락토바실푸스 플란타룸에 차를 첨가함으로써 SOD형 활성 및 CAT 활성이 발현될 뿐만 아니라, MnC12와 같은 무기 화합물에 함유된 Mn과 비교하여 장시간 동안 높은 활성이 보유된다. 이는 위장에서 생존가능한 세포수가 유지되기 때문인 것으로 간주된다.As described above, addition of tea to Lactobacillus plantarum not only expresses SOD activity and CAT activity, but also retains high activity for a long time compared with Mn contained in inorganic compounds such as MnC12. This is considered to be because viable cell numbers are maintained in the stomach.
시험 실시예 3Test Example 3
(락트산 발효 전후 차의 수용성 분획의 SOD형 활성)(SOD-type Activity of Water-Soluble Fraction of Tea Before and After Lactic Acid Fermentation)
상술한 바와 같이, 차를 가할 경우 높은 SOD형 활성이 수득된다. 실제로, 차(분말녹차)를 50μM의 농도(Mn의 농도)로 APT 배양액에 가하고 배지를 상온에서 24시간 돌안 정지시켜 수용성 분획(발효전 배지의 상청액)을 수득한다. 이어서, 수용성 분획의 SOD형 활성을 측정한다. 결과로서, 제5도에 나타낸 바와 같이 발효전 SOD형 활성은 54.040U/APT 배양액 200ml로 높다.As described above, high SOD activity is obtained when a difference is added. In fact, tea (powder green tea) is added to the APT culture at a concentration of 50 μM (concentration of Mn) and the medium is stopped at room temperature for 24 hours to obtain an aqueous fraction (supernatant of the medium before fermentation). Next, the SOD type activity of the water soluble fraction is measured. As a result, as shown in FIG. 5, the SOD-type activity before fermentation was as high as 200 ml of 54.040U / APT culture.
한편, 50μM의 농도(Mn의 농도)로 Mn이 가해진 상기의 차-첨가된 APT 배양액을 락토바실루스 글란타룸으로 접종시켜 16시간 동안 발효시켜 수득한 수용성 분획 의 SOD형 활성을 측정한다. 그 결과, 제5도에 나타낸 바와 같이 발효후 SOD형 활성은 93.400U/APT 배양액 200ml이다.Meanwhile, the SOD-type activity of the water-soluble fraction obtained by inoculating the above-added APT culture with Mn at a concentration of 50 μM (concentration of Mn) inoculated with Lactobacillus glutarum and fermenting for 16 hours. As a result, as shown in FIG. 5, SOD-type activity after fermentation was 93 ml of 93.400 U / APT culture.
상기 결과로부터, 발효에 의해 발효전보다 활성이 약 1.7배 증가함을 알 수 있다. 그 이유는 다음과 같다고 여겨진다. 즉, 항산화 성분은 차를 락토바실루스 플란타룸에 이들함으로써 보다 유효한 형태로 존재할 수 있다. 이로부터 락토바실루스 플란타룬에 파를 가하는 효과를 확인할 수 있다.From the above results, it can be seen that by fermentation, the activity is increased by about 1.7 times. The reason is considered as follows. That is, the antioxidant component may be present in a more effective form by making tea into Lactobacillus plantarum. From this, the effect of adding a wave to Lactobacillus plantaroon can be confirmed.
시험 실시예 4Test Example 4
(락토바실루스 플란타룸으로 발효시켜 제조한 생성물의 경구 투여에 의한 위점막 병변의 억제 )(Inhibition of gastric mucosal lesions by oral administration of a product prepared by fermentation with Lactobacillus plantarum)
(1) 인도메타신 위궤양 모델에서의 효과(1) Effect on indomethacin gastric ulcer model
인도메타신 20mg/kg은 SD 숫컷 랫트(중량: 250g)에 피하 주사하고 6시간 후락토바실루느 플란나룸으포 발효시켜 제조된 생성물의 위궤양 형성에 대한 효과를 조사한다. 락토바실루스 플란하룸으로 발효시켜 제조된 생성물은 50μM의 농도(Mn의 농도)로 APT 배양액에 차 추출액(열수 1로 녹차 100g을 추출하여 수득)을 가하여 수득한 것을 락토바실루스 플란타룸으로 접종시켜 16시간 동안 발효시킨 것이다.Indomethacin 20 mg / kg was injected subcutaneously into SD male rats (weight: 250 g) and examined for the effect on gastric ulcer formation of the product prepared by fermentation with Fructobacilli Flanarum for 6 hours. The product produced by fermentation with Lactobacillus Planharum was extracted in APT culture at 50 μM concentration (Mn concentration). Extracted with 100 g of green tea) was inoculated with Lactobacillus plantarum and fermented for 16 hours.
시험 생성물은 다음과 같다.The test product is as follows.
(a) 락토바실루스 플란타룸으로 발효시켜 제조한 차-첨가된 생성물 그룹: SOD형 활성이 24.000U/ml가 되도록 차추출액을 제조하고 차 추출액을 락토바실루스 플란타룸으로 발효시켜 제조한 생성물에 가하여 수득한다. 락토바실루스 플란타룸의 생존가능한 세포수는 6.3×109개의 세포/ml이다.(a) Tea-added product group prepared by fermentation with Lactobacillus plantarum: A tea extract was prepared to have a SOD-type activity of 24.000 U / ml and the tea extract was fermented with Lactobacillus plantarum to Obtained by addition. The viable cell number of Lactobacillus plantarum is 6.3 × 10 9 cells / ml.
(c) 대조 그룹: APT 배양액만(c) control group: APT culture only
인도메타신을 피하주사 후 3시간마다 2.5ml의 용량으로 시험 생성물을 2회 경구 투여한다.The test product is orally administered twice at a dose of 2.5 ml every three hours after subcutaneous injection of indomethacin.
시험 결과는 제6도에 도시되어 있다. 제6도는 랫트 10마리의 평균값을 ± 표준오차로 인도메타신 피하주사한지 6시간 후애 각각의 그룹의 궤양 지수를 나타내는 그래프이다. 제6도에 나타낸 바와같이, 대조 그룹의 궤양 지수는 5.8± 1.8mm이다. 또한, 궤양은 대조 그룹의 10마리 랫트에서 모두 발생됨을 알 수 있다. 반대로 락토바실루느 플란나룸으로 발효시켜 제조한 생성물 그룹에서는 대조그룹과 비교하여 상당히 억제되었다(p < 0.05).The test results are shown in FIG. FIG. 6 is a graph showing the ulcer index of each group 6 hours after subcutaneous injection of indomethacin with the mean value of 10 rats by ± standard error. As shown in Figure 6, the ulcer index of the control group is 5.8 ± 1.8 mm. It can also be seen that ulcers occur in all 10 rats of the control group. In contrast, the product group prepared by fermentation with lactobacillus flanarum was significantly inhibited compared to the control group (p <0.05).
시험 생성물 투여 후, 궤양 지수에 기인한 평가를 하고 혈청 단백질 제거된 성분에 존재하는 SOD형 활성을 측정한다. 그 결과, 제7도에 도시된 바와같이, 대조 그룹에서 단백질 제거된 성분중 SOD형 활성은 0.23±0.08U/ml이다. 반대로 락토바실루느 플란타룸으로 발효시켜 제조한 차-첨가된 생성물 그룹은 상당한 증가,2.34±0.33U/ml(p<001)를 나타낸다.After administration of the test product, an assessment due to the ulcer index is made and the SOD type activity present in the serum protein depleted component is measured. As a result, as shown in FIG. 7, the SOD type activity in the protein-depleted components in the control group was 0.23 ± 0.08 U / ml. In contrast, the tea-added product group prepared by fermentation with lactobacillus plantarum shows a significant increase, 2.24 ± 0.33 U / ml (p <001).
(2) 과산화수소로 유발된 위점막 병변 모델에서의 효과(2) Effect on gastric mucosal lesion model induced by hydrogen peroxide
과산화수소로 인한 위점막 병변을 발생시키기 위해, SD 숫컷 랫트(중량: 250g)유문 결착시키고 디에틸말레산(0.75ml/kg)을 조직에 글루타티온 고갈제로서 피하주사한다.이어서, 7.5% 과산화수소 0.5ml를 투여하고 3시간 후에 락토바실루스 플란타룸으로 발효시켜 제조한 생성물의 .처점막 병변에 대한 효과를 조사한다.To develop gastric mucosal lesions due to hydrogen peroxide, SD male rats (weight: 250 g) are pylori bound and diethylmaleic acid (0.75 ml / kg) is injected subcutaneously into the tissue as glutathione depleting agent, followed by 0.5 ml of 7.5% hydrogen peroxide. The effect of the product prepared by fermentation with Lactobacillus plantarum 3 hours after administration of.
락토바실루스 플란다룸으로 발효시켜 제조한 생성물로서는, 50μM의 농도(Mn의 농도)로 APT 배양액에 MgCl2 또는 차 추출액(역수 1로 녹차 100g을 추출하여 수득)을 가하고 락토바실루스 플란타룸으포 접종시킨 후 16시간 동안 발효시켜 수득한 것이다.As a product prepared by fermentation with Lactobacillus flandarum, MgCl2 or tea extract (obtained by extracting 100 g of green tea with reciprocal 1) was added to APT culture at a concentration of 50 μM (concentration of Mn) and inoculated with Lactobacillus plantarumpo. After fermentation for 16 hours.
시험 생성물은 다음과 같다.The test product is as follows.
(a) 락토바식루스 플란타룸으로 발효시켜 제조한 생성물 그룹: MnCl2로 발효시켜 수득한다.(a) Product group prepared by fermentation with Lactobacillus plantarum: obtained by fermentation with MnCl2.
(b) 락토바실루스 플란타룸으로 발효시켜 제조한 차-첨가된 생성물 그룹: SOD형 활성이 24.000U/ml가 되도록 차 추출액을 제조하고 차 추출액을 락토바실루스 플란타룸으로 발효시켜 제조한 차-첨가된 생성물에 가하여 수득한다. 락토바실루스 플란타룸의 생존가능한 세포수는 6.3×109개의 세포/ml이다.(b) tea-added product groups prepared by fermentation with Lactobacillus plantarum: tea extracts prepared by fermenting tea extracts with Lactobacillus plantarum to have a SOD-type activity of 24.000 U / ml; Obtained by addition to the added product. The viable cell number of Lactobacillus plantarum is 6.3 × 10 9 cells / ml.
(c) 차 그룹: SOD형 활성이 2.400U/ml가 될 수 있도록 차 추출액을 제조하고 APT 배양액에 차 추출액을 가하여 수득한다.(c) Tea group: A tea extract was prepared so that the SOD-type activity was 2.400 U / ml and obtained by adding the tea extract to the APT culture.
(d) 대조 그룹: APT 배양액만(d) Control group: APT culture only
과산화수소 투여 직전 시험 생성물을 2.5ml의 용량으로 경구투여한다.The test product is administered orally at a dose of 2.5 ml immediately prior to administration of hydrogen peroxide.
결과는 제8도에 도시되어 있다. 제8도는 랫트 10마리의 위점막 병변 지수(면적%)의 평균값±표준오차를 나타내는 그래프이다. 제8도에 나타낸 바와 같이, 미란 영역은 대조 그룹에서 30.60±6.34%이다. 이와는 반대로, 차 그룹 및 락토바실루스 플란타룸으로 발효시켜 제조한 생성물 그룹에서 미란의 총면적은 각각22.38±5.59% 및 20.32±8.05%이며, 대조 그룹과 살당한 차이를 나타내지는 않는다. 한편, 락토바실루스 플란타룸으로 발효시켜 제조한 차-첨가된 생성물 그룹에서 미란의 총면적은 4.46±2.12%이며 대조 그룹과 비교하여 상당한 억제 효과를 보인다(p < 0.05).The results are shown in FIG. 8 is a graph showing the mean value ± standard error of the gastric mucosal lesion index (area%) of 10 rats. As shown in FIG. 8, the erosion area is 30.60 ± 6.34% in the control group. In contrast, the total area of erosion in the tea group and the product group produced by fermentation with Lactobacillus plantarum was 22.38 ± 5.59% and 20.32 ± 8.05%, respectively, showing no killing difference from the control group. On the other hand, the total area of erosion in the tea-added product group prepared by fermentation with Lactobacillus plantarum was 4.46 ± 2.12% and showed a significant inhibitory effect compared to the control group (p <0.05).
(3) 결과(3) results
인도메탄신 유발된 위궤양 모델에서, 락토바실루스 플란타룸으로 발효시켜 제조한 차-첨가된 생성물로 인한 위궤양 형성 억제 효과를 확인할 수 있다. 또한, 과산화수소로 유발된 위점막 병변 모델에서 락토바실루스 플란타룸 세포 또는 차단독 투여 효과는 관찰되지 않는다. 억제 효과는 이들을 함께 사용할 경우 관찰된다.In the indomethane-induced gastric ulcer model, the effect of inhibiting gastric ulcer formation due to the tea-added product prepared by fermentation with Lactobacillus plantarum can be confirmed. In addition, no effect of lactobacillus plantarum cells or blocking venom administration was observed in a gastric mucosal lesion model induced by hydrogen peroxide. Inhibitory effects are observed when used together.
지금까지는 인도메타신에 의한 위궤양 형성은 점막 내성 저하 및 프로스타글란딘의 형성 억제에 의한 혈액 흐름 저하에 의한 것으로 설명되어 왔다. 최근 보고에 따라, 이는 아라키돈산 대사 과정 및 호중구 침윤에 의한 활성 산소와 관련되는 것으로 확인된다. 이때 사용된 인도메타신의 피하투여는 투여된 부분으로부터 혈액을 통해 위점막에 작용하기 때문에 이는 위점막 소화기관에서 생성된 활성 산소와 관련된다고 간주된다.Until now, gastric ulcer formation by indomethacin has been explained by lowering blood flow by lowering mucosal resistance and inhibiting the formation of prostaglandins. According to recent reports, it has been found to be associated with free radicals by arachidonic acid metabolic processes and neutrophil infiltration. Since the subcutaneous administration of indomethacin used acts on the gastric mucosa through the blood from the administered portion, it is considered to be related to free radicals produced in the gastrointestinal mucosa.
위궤양 형성은 차-첨가된 락토바실루스 플란타룸에 의해 억제되며, 동시에 혈청에서 단백질 제거된 성분의 SOD형 활성이 증가한다. 따라서, 차의 항산화 물질은 흡수되어 위 점막에서 활성 산소를 제거한다고 간주된다. 과산화수소의 경구 투여로 인한 위점막 병변의 예는 과산화수소로 인한 위점막의 직접 질환 및 호중구 침윤을 통한 간접 질환을 포함한다. 두 경우에서, 위의 내강에 존재하는 과산화수소는 유도물질로서 작용한다. 과산화수소에 의해 유발된 위점막 병변이 차 및 락토바실루스 플라타룸 세포를 함께 투여함으로써 억제된다는 사실은 락토바실루스 플라타룸 세포의 Mn-CAT 활성이 위의 내강에서 효과적으로 작용함을 의미한다. 한편, 락토바실루스 플란타룸 세포만을 투여하면 효과적인 억제 효과가 나타나지 않는다는 사실은 세포의 CAT 활성이 위의 내강에서 작용하지 않음을 의미하며, 이는 시험 실시예 2의 결과를 반영한다.Gastric ulcer formation is inhibited by tea-added Lactobacillus plantarum, while at the same time increasing the SOD type activity of the protein depleted in serum. Thus, the antioxidants in tea are considered to be absorbed to remove free radicals from the gastric mucosa. Examples of gastric mucosal lesions due to oral administration of hydrogen peroxide include direct diseases of the gastric mucosa due to hydrogen peroxide and indirect diseases through neutrophil infiltration. In both cases, hydrogen peroxide in the gastric lumen acts as an inducer. The fact that gastric mucosal lesions induced by hydrogen peroxide is inhibited by co-administration of tea and Lactobacillus platarum cells means that Mn-CAT activity of Lactobacillus platarum cells works effectively in the gastric lumen. On the other hand, the fact that administration of only Lactobacillus plantarum cells does not show an effective inhibitory effect means that the CAT activity of the cells does not work in the gastric lumen, reflecting the results of Test Example 2.
시험 실시예 5Test Example 5
(차 추출물 및 카테친의 MPO(마이펠로퍼옥시다제) 활성 억제 작용)(Inhibitory Effect of Tea Extract and Catechin on MPO (Myfellow Peroxidase) Activity)
호준구는 생체내에서 이물질 및 박테리아의 해독을 위해 활성 산소를 생산하는 것으로 공지되어 있다. 특히, 호중구는 "MPO"로 언급되는 과산화수소의 디스뮤테이트된(dismutated) 시스템을 가지며 따라서 세포독성이 높은 과염소산 또는 모노클로르아민을 생성한다. 과도한 반응시에, MPO의 외부로 MPO가 스며나오는 것이 확실하며 이는 생체막 질병은 야기하는 한 인자인 것으로 간주된다. 또한, 호중구의 침윤이 인도메타신-유발된 위궤양 및 과산화수소-유발된 위점막 병변에서 중요 메카니즘과 관련된다는 보고가 있다.Hojungu is known to produce free radicals for the detoxification of foreign bodies and bacteria in vivo. In particular, neutrophils have a dismutated system of hydrogen peroxide referred to as "MPO" and thus produce high cytotoxic perchloric acid or monochloramine. In case of excessive reaction, it is certain that MPO is seeping out of MPO, which is considered to be one factor that causes biomembrane disease. It is also reported that neutrophil infiltration is associated with an important mechanism in indomethacin-induced gastric ulcer and hydrogen peroxide-induced gastric mucosal lesions.
본 발명에서 망간-함유 천연 물질로서 사용되는 차를 첨가하는 의미는 상술한 바와 같다. 또한, 차 성분이 MPO 활성을 억제하는지의 여부를 시험관내에서 조사한다.The meaning of adding the tea used as the manganese-containing natural material in the present invention is as described above. In addition, it is investigated in vitro whether the tea components inhibit MPO activity.
0.1% 과산화수소 및 1.03mM o-디아니시딘을 함유하는 50mM 인산염 완충액(pH5.4) 2.9ml에 시험용액 50μl 및 MPO 정제 효소(1.24U/ml) 50μl를 가하고 25℃ 큐벳에서 배양한 후 5분 동안 흡수( =450nm)변화를 측정한다. 블랭크로서, 50mM인산염 완충액(pH 5.4) 50μl를 사용한다.To 2.9 ml of 50 mM phosphate buffer (pH5.4) containing 0.1% hydrogen peroxide and 1.03 mM o-Dianisidine, 50 μl of test solution and 50 μl of MPO purified enzyme (1.24 U / ml) were added and incubated in a 25 ° C. cuvette for 5 minutes. The change in absorption (= 450 nm) is measured. As blank, 50 μl of 50 mM phosphate buffer (pH 5.4) is used.
시험 용액으로서, 녹차를 열수로 추출하여 수득한 차 추출액 및 차 추출액중의 Mn 농도를 즉진하고 배지중 Mn의 농도가 차 추출액의 Mn 농도와 같도록 APT 배양액에 MnCl2를 가하여 수득한 용액을 사용한다. 이어서, MPO 활성 억제율을 Mn의 각 농도에서 평가한다. 결과는 제9도에 도시되어 있다.As a test solution, a tea extract obtained by extracting green tea with hot water and a solution obtained by adding MnCl 2 to the APT culture medium immediately after the concentration of Mn in the tea extract and the concentration of Mn in the medium are equal to the Mn concentration of the tea extract are used. . The rate of inhibition of MPO activity is then evaluated at each concentration of Mn. The results are shown in FIG.
제9도로부터 명백한 바와 같이, 차 추출액은 MPO 효소 활성을 억제하며 Mn농도가 높아짐에 따라 억제 활성도 높아진다. 또한, 동일 농도의 Mn 용액과 비교하여 억제율이 높다. 이는 Mn 이외의 차 성분과 관련되는 것으로 간주된다.As is apparent from FIG. 9, the tea extract inhibits MPO enzyme activity, and as the Mn concentration increases, the inhibitory activity also increases. Moreover, the inhibition rate is high compared with Mn solution of the same concentration. This is considered to be related to difference components other than Mn.
따라서, Mn 이외의 차에 함유된 성분이 MPO 활성 억제와 관련되는지 여부를 조사한다. 즉, 상술한 바와 동일한 방법으로 Mn 이외의 성분으로서 정제된 카테친을 사용하여 MPO 억제 활성을 조사한다. 결과는 제10도에 도시되어 있다. 제10도로부터 명백한 바와 같이, 카태친을 1.5μg/ml 이상의 농도에서 억제 효과를 나타낸다.Therefore, it is investigated whether components contained in tea other than Mn are related to the inhibition of MPO activity. That is, MPO inhibitory activity is investigated using catechin purified as a component other than Mn by the same method as mentioned above. The results are shown in FIG. As is apparent from FIG. 10, catechin exhibits an inhibitory effect at a concentration of 1.5 μg / ml or more.
상술한 바와 같이, 차 성분으로 인한 MPO 활성 억제가 확실하며, 동시에 Mn 및 카테친은 이의 활성 억제와 관련되는 것이 명백하다.As mentioned above, it is evident that inhibition of MPO activity due to tea components is evident, while at the same time Mn and catechin are associated with their inhibition of activity.
실시예 1(요거트형)Example 1 (yoghurt type)
멸균 우유 1에, 차(분말 녹차) 4g을 가한다. 차를 가한 우유에 락토바실루스 플란타룸을 접종시킨다. 이어서 35 내지 37℃의 온도를 유지하면서 18시간 동안 발효시 킨다.Sterile Milk 1 To this, 4 g of tea (powdered green tea) is added. Inoculate lactobacillus plantarum into the milk with tea. It is then fermented for 18 hours while maintaining a temperature of 35 to 37 ℃.
통상의 방법에 따라서, 가해진 차의 양, 발효 시간 등과 같은 제조 조건을 조절함으로써 하기의 요거트 형태를 제조할 수 있다.According to a conventional method, the following yoghurt forms can be prepared by adjusting the production conditions such as the amount of tea added, fermentation time and the like.
a. 고형(정치 요거트)a. Solid (political yogurt)
b. (반)고형(교반 요거트)b. (Semi) solid (stirring yoghurt)
c 액상(음료형 요거트)c Liquid (beverage yogurt)
실시예 2(유산균 음료형)Example 2 (lactic acid bacteria beverage type)
차(분말 녹차)를 탈지유 및 수크로즈의 혼합 용액의 예정량에 가하고 락토바실루스 플란타룸을 혼합 용액에 접종한 후 37℃의 온도를 유지하면서 18시간 동안 발효시킨다. 그후, 발효 용액을 물로 회석하고 안정화제 및 향료를 가하여 액상요거트형 유산균 음료를 수득한다. 이의 조성은 표 1에 기재되어 있다.Tea (powdered green tea) is added to a predetermined amount of the mixed solution of skim milk and sucrose, and lactobacillus plantarum is inoculated into the mixed solution and then fermented for 18 hours while maintaining a temperature of 37 ° C. Thereafter, the fermentation solution is diluted with water and stabilizers and flavors are added to obtain a liquid yoghurt type lactic acid bacteria beverage. Its composition is listed in Table 1.
실시예 3(유산균 음로형)Example 3 (lactic acid bacteria negative type)
차(분말 녹차)로서 단일 세포 차(Single Cell Foods, Co., Ltd. 제조)를 탈지유 및 슈크로즈의 혼합 용액의 예정량에 가하고 락토바실루스 플란타룸을 혼합 용액에 접종한 후 37℃의 온도를 유지하면서 18시간 동안 발효시킨다. 그후, 발효액을 물 및 오렌지 쥬스로 희석하고 안정화제 및 향료를 가하여 쥬스형 유산균 음료를 수득한다. 이의 조성은 표 1에 기재되어 있다.As a tea (powder green tea), a single cell tea (manufactured by Single Cell Foods, Co., Ltd.) was added to a predetermined amount of a mixed solution of skim milk and sucrose, and lactobacillus plantarum was inoculated into the mixed solution, followed by a temperature of 37 ° C. Ferment for 18 hours while maintaining. Thereafter, the fermentation broth is diluted with water and orange juice and stabilizer and flavor are added to obtain a juice type lactic acid bacteria beverage. Its composition is listed in Table 1.
[표 1]TABLE 1
1) : 안정화제, 향료 등1): stabilizer, fragrance, etc.
실시예 4(동결 건조형)Example 4 (freeze drying type)
약 5 × 1010개의 박테리아 세포(락토바실루스 플란타룸), 차(분말 녹차) 4g,및 락토즈 및 글루코즈와 같은 부형제를 혼합하고 혼합물을 동결 건조시켜 정제형 동결 건조 제품을 수득한다. 이 제품은 그대로 섭취하기에 적합하다.About 5 × 10 10 bacterial cells (Lactobacillus plantarum), 4 g of tea (powder green tea), and excipients such as lactose and glucose are mixed and the mixture is lyophilized to obtain a tablet freeze-dried product. This product is suitable for consumption.
실시예 5(동결 건조형)Example 5 (freeze drying type)
약 5 × 108개의 박테리아 세포(락토바실루스 플란타룸), 차(분말 녹차) 4g및 락토즈 및 글루코즈와 같은 부형제를 혼합하고 혼합물을 동결 건조시켜 정제형 동결 건조 제품을 수득한다. 이 생성물을 시판 우유에 가하고 혼합물을 실온에서 12내지 24시간 동안 발효시킨다. 그 결과, 요거트를 제조할 수 있다. 따라서,동결 건조 제품은 보통 가정에서 요거트를 제조하는데 적합하다.Approximately 5 x 108 bacterial cells (Lactobacillus plantarum), 4 g of tea (powder green tea) and excipients such as lactose and glucose are mixed and the mixture is lyophilized to obtain a tablet freeze-dried product. This product is added to commercial milk and the mixture is fermented at room temperature for 12 to 24 hours. As a result, yoghurt can be manufactured. Thus, freeze dried products are usually suitable for making yoghurt at home.
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10964393 | 1993-05-11 | ||
JP93-109643 | 1993-05-11 | ||
PCT/JP1994/000753 WO1994026133A1 (en) | 1993-05-11 | 1994-05-09 | Antioxidant food, antioxidant preparation and antioxidization method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950702391A KR950702391A (en) | 1995-07-29 |
KR100236373B1 true KR100236373B1 (en) | 1999-12-15 |
Family
ID=14515488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950700078A KR100236373B1 (en) | 1993-05-11 | 1994-05-09 | Antioxidant food and antioxidant preparation |
Country Status (9)
Country | Link |
---|---|
US (2) | US6228358B1 (en) |
EP (1) | EP0649603B1 (en) |
KR (1) | KR100236373B1 (en) |
AU (1) | AU670378B2 (en) |
CA (1) | CA2139937C (en) |
DE (1) | DE69426186T2 (en) |
DK (1) | DK0649603T3 (en) |
TW (1) | TW360539B (en) |
WO (1) | WO1994026133A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102196276B1 (en) * | 2020-05-19 | 2020-12-29 | 주식회사 아미코스메틱 | Probiotic composition comprising green tea fermented extract having antibacterial activity against acne-causing resident skin flora and antioxidant efficacy |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08322464A (en) * | 1995-05-26 | 1996-12-10 | Yakult Honsha Co Ltd | Yogurt containing bifidobacterium cell body and its production |
JPH10179024A (en) * | 1996-12-20 | 1998-07-07 | Yahagi:Kk | Processed milk |
PL347029A1 (en) * | 1998-10-01 | 2002-03-11 | Probi Ab | Reduction of oxidative stress factors |
ES2238285T3 (en) * | 1999-05-07 | 2005-09-01 | Compagnie Gervais Danone | USE OF ACIDOLACTIC BACTERIES IN THE PREPARATION OF FERMENTED MILKS FOR THE TREATMENT OF REDUCED IMMUNE LEVELS. |
KR100753012B1 (en) | 1999-08-03 | 2007-08-30 | 가부시키가이샤 야쿠루트 혼샤 | Fermented milks and their production processes |
US6989161B2 (en) * | 2000-06-12 | 2006-01-24 | Access Business Group International Llc | Phytonutrient nutritional supplement |
FR2834718B1 (en) * | 2002-01-15 | 2004-12-24 | Cognis France Sa | COSMETIC AND / OR PHARMACEUTICAL ACTIVE SUBSTANCES |
US6953574B2 (en) * | 2002-06-21 | 2005-10-11 | Technology Commercialization, Inc. | Method for producing a fermented hydrolyzed medium containing microorganisms |
JP4149836B2 (en) * | 2003-02-27 | 2008-09-17 | 独立行政法人科学技術振興機構 | Dihydroxybenzoate derivative, process for producing the same and use thereof |
JP2005097222A (en) * | 2003-08-26 | 2005-04-14 | Toyo Shinyaku:Kk | Fermented product of allium cepa l. |
GB0424552D0 (en) * | 2004-11-05 | 2004-12-08 | Cambridge Theranostics Ltd | Methods and means |
US8182849B2 (en) | 2005-02-23 | 2012-05-22 | Otsuka Pharmaceutical Co., Ltd. | Fermented tea beverage and tea beverage |
CA2596794C (en) * | 2005-02-23 | 2013-01-29 | Otsuka Pharmaceutical Co., Ltd. | Tea-based fermentation beverage and tea beverage |
JP4800015B2 (en) * | 2005-11-22 | 2011-10-26 | 株式会社カロッツェリアジャパン | Microbial cultures for suppressing the onset of dermatitis and products using them |
TWI491362B (en) * | 2006-12-01 | 2015-07-11 | Meiji Co Ltd | A method of manufacture fermented milk, and fermented milk |
JP2008199905A (en) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | Improving agent for survivability of lactic acid bacterium |
US8735089B2 (en) | 2010-01-08 | 2014-05-27 | Compagnie Gervais Danone | Method for selecting bacteria with anti-oxidant action |
BR112012016894A2 (en) | 2010-01-08 | 2015-09-15 | Gervais Danone Sa | lactobacilli with antioxidant action. |
CN102851259B (en) * | 2011-06-28 | 2015-05-06 | 花王株式会社 | Preparation method of antioxidant |
CN102771874A (en) * | 2012-07-16 | 2012-11-14 | 南京中医药大学 | Natural food preservative and preparation method and applications thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT248366B (en) * | 1961-05-05 | 1966-07-25 | Hufnagl Walter | Roller set for tool heads for producing smooth or ribbed wires or rods |
GB1197257A (en) * | 1968-05-22 | 1970-07-01 | Seiji Kuwabara | Fermented Milk |
SU376078A1 (en) * | 1971-02-16 | 1973-04-05 | Московский ордена Трудового Красного Знамени институт народного хоз йства имени Г. Б. Плеханова | HANGING CABBAGE |
US4029819A (en) * | 1973-04-16 | 1977-06-14 | Etablissement Public Det: Agence Nationale De Valorisation De La Recherche Anver | Superoxide dismutase and its application as an oxidation inhibitor |
LU71110A1 (en) * | 1974-10-15 | 1976-11-11 | ||
JPS51115968A (en) * | 1975-04-01 | 1976-10-13 | Yoshihide Hagiwara | Production of lactic acid fermented food of green plant |
US4230595A (en) * | 1978-03-13 | 1980-10-28 | Teijin Limited | Oxygen scavenging and heat-generating compositions, and deoxygenating and heat-generating structures |
JPS557013A (en) * | 1978-06-29 | 1980-01-18 | Kibun Kk | Preparation of yogurt containing vegetable |
DE3024076A1 (en) * | 1980-02-11 | 1981-08-20 | Anders Marius Holte Vognsen | METHOD FOR PRODUCING A PREPARATION CONTAINING MINERALS |
US4870002A (en) * | 1981-04-07 | 1989-09-26 | The United States Of America As Represented By The Secretary Of The Air Force | Method of prevention of oxidative injury to cells |
JPS59219384A (en) * | 1983-05-30 | 1984-12-10 | Mitsui Norin Kk | Preparation of natural antioxidant |
LU85910A1 (en) * | 1985-05-22 | 1986-12-05 | Oleofina Sa | PROCESS FOR REMOVING OXYGEN FROM FOODS AND BEVERAGES, AND ENZYMATIC COMPOSITION USED THEREFOR |
AU6400686A (en) * | 1985-10-14 | 1987-05-05 | Izumi, K. | Antioxidative biophylactic agents |
JPS62201570A (en) * | 1986-02-18 | 1987-09-05 | Shin Nippon Kagaku Kogyo Kk | Preparation of dried cell of survival bifidus bacteria |
US5284871A (en) * | 1987-09-25 | 1994-02-08 | The Pillsbury Company | Oxygen removal |
JPH01243971A (en) * | 1988-03-25 | 1989-09-28 | Kagome Kk | Lactic fermentation drink and production thereof |
JPH023495A (en) * | 1988-06-13 | 1990-01-09 | Okuno Seiyaku Kogyo Kk | Antioxidant |
JPH06104059B2 (en) | 1989-03-30 | 1994-12-21 | 株式会社クボタ | New lactic acid bacteria |
GB8919661D0 (en) * | 1989-08-31 | 1989-10-11 | Univ Alberta | Superoxide dismutase-catalase conjugates |
JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
JPH07100025B2 (en) * | 1991-04-17 | 1995-11-01 | アサヒビール株式会社 | Novel lactic acid bacterium and fermented ginseng juice obtained using it |
JP3630436B2 (en) * | 1991-11-13 | 2005-03-16 | 株式会社創研 | Active oxygen scavenger from rice |
US5498412A (en) * | 1993-12-10 | 1996-03-12 | A.O.A. Japan Co., Ltd. | Antioxidant composition and method for the same |
-
1994
- 1994-05-09 EP EP94914597A patent/EP0649603B1/en not_active Expired - Lifetime
- 1994-05-09 DE DE69426186T patent/DE69426186T2/en not_active Expired - Fee Related
- 1994-05-09 AU AU66900/94A patent/AU670378B2/en not_active Ceased
- 1994-05-09 CA CA002139937A patent/CA2139937C/en not_active Expired - Fee Related
- 1994-05-09 KR KR1019950700078A patent/KR100236373B1/en not_active IP Right Cessation
- 1994-05-09 US US08/367,223 patent/US6228358B1/en not_active Expired - Fee Related
- 1994-05-09 DK DK94914597T patent/DK0649603T3/en active
- 1994-05-09 WO PCT/JP1994/000753 patent/WO1994026133A1/en active IP Right Grant
- 1994-05-11 TW TW083104234A patent/TW360539B/en not_active IP Right Cessation
-
2001
- 2001-12-21 US US10/023,796 patent/US6884415B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102196276B1 (en) * | 2020-05-19 | 2020-12-29 | 주식회사 아미코스메틱 | Probiotic composition comprising green tea fermented extract having antibacterial activity against acne-causing resident skin flora and antioxidant efficacy |
Also Published As
Publication number | Publication date |
---|---|
CA2139937C (en) | 2003-09-09 |
EP0649603B1 (en) | 2000-10-25 |
DE69426186T2 (en) | 2001-05-17 |
AU670378B2 (en) | 1996-07-11 |
WO1994026133A1 (en) | 1994-11-24 |
US6228358B1 (en) | 2001-05-08 |
EP0649603A4 (en) | 1995-10-25 |
US20020064518A1 (en) | 2002-05-30 |
US6884415B2 (en) | 2005-04-26 |
CA2139937A1 (en) | 1994-11-24 |
DE69426186D1 (en) | 2000-11-30 |
EP0649603A1 (en) | 1995-04-26 |
DK0649603T3 (en) | 2000-11-27 |
KR950702391A (en) | 1995-07-29 |
AU6690094A (en) | 1994-12-12 |
TW360539B (en) | 1999-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100236373B1 (en) | Antioxidant food and antioxidant preparation | |
EP1181027B1 (en) | Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria | |
AU750136B2 (en) | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS | |
KR100661032B1 (en) | Composition for Improving Liver Function, Reduction of Serum Ethanol Level, and Antioxidation | |
CN100469869C (en) | Embedding protection method for beneficial bacteria of intestinal tract | |
US20120020942A1 (en) | Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori | |
US20080193429A1 (en) | Probiotic lactic acid bacterium to treat bacterial infections associated with sids | |
KR101992537B1 (en) | Novel Lactobacillus sakei and compositions comprising the same | |
JP2002522393A (en) | Method for increasing the solubility of nutrient materials using symbiotic lactic acid producing bacteria | |
JP3784045B2 (en) | LDL oxidation-suppressing food and drink and pharmaceuticals | |
WO2002032441A1 (en) | Bone metabolism improving agent | |
WO1998057555A1 (en) | Fermentation products and method for preventing food poisoning | |
AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
JP2003253262A (en) | Antioxidant | |
KR20170106187A (en) | Antioxidant Composition | |
JP5020134B2 (en) | Food composition for improving sugar metabolism and / or food composition for reducing visceral fat | |
JP2894837B2 (en) | Antioxidant food, antioxidant preparation and antioxidant method | |
KR100527103B1 (en) | Composition comprising microorganism having lipid metabolism-improving activity for prevention and treatement of geriatric diseases and the use thereof | |
JPH0899888A (en) | Glutathione peroxidase activator | |
KR101376629B1 (en) | New Lactobacillus arizonensis BCNU 9200 and probiotics composition comprising the same | |
CEYHAN et al. | PRODUCTION OF PROBIOTIC JUICE IN FRUIT MATRIX | |
JPH06116155A (en) | Serum cholesterol lowering agent | |
JPH09227391A (en) | Suppressant for cytolytic activity in alimentary canal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20070920 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |